Ml. Bertolaccini et al., Plasma tumor necrosis factor alpha levels and the-238*A promoter polymorphism in patients with antiphospholipid syndrome, THROMB HAEM, 85(2), 2001, pp. 198-203
Objectives. To explore the possible involvement of the proinflammatory and
prothrombotic cytokine TNF alpha in APS by determining the plasma levels in
patients and to test for association of TNFA promoter polymorphisms and HL
A class II genotypes with both plasma TNF alpha and disease. Patients and M
ethod. We studied 83 Caucasoid patients with APS and two groups of healthy
controls. TNFa levels were determined in plasma from 35 patients' and 21 co
ntrols using a highly sensitive sandwich ELISA. The full patient group was
genotyped together with 95 ethnically matched healthy controls. -308 and -2
38 TNFA promoter polymorphisms were assessed by ARMS-PCR. HLA-DQB1, DQA1 an
d DRB1 genotypes were determined by PCR using sequence specific primers. Re
sults. TNF alpha levels were significantly higher in patients with APS than
healthy controls (median 2.95 pg/ml [range 0.51-10.75] vs. 0.95 pg/ml [0.5
1-1.6]. respectively; p = 0.0001). Frequencies of TNFA-308*2 genotype did n
ot differ between patients and controls. In contrast, TNFA-238*A positive g
enotype was more frequent in APS patients with arterial thrombosis and preg
nancy loss than in controls (OR 3.7 [95% CI 1.37-10.1], p = 0.007 and OR 3.
95 [95% CI 1.3-11.7], p = 0.01: respectively). DQB1*0303-DRB1*0701 haplotyp
e was associated with TNFA-238*A in the control group (OR 96.0 [95% CI 9.6-
959], p<0.0001) as well as in APS patient's group (OR 54.2 [95% CI 9.6-306.
5]. p<0.0001). Conclusions. Raised plasma TNFa levels were found in patient
s with APS. As a prothrombotic and proinflammatory cytokine, TNFa may be in
volved in the development of clinical features of APS. The lack of correlat
ion between the TNFA-238 polymorphism and plasma levels associated with dis
ease suggests that the TNF genetic marker may only indirectly relate to pro
tein levels by virtue of allelic association with a functional marker which
may reside in the HLA class II region.